The NCLs (neuronal ceroid lipofuscinoses) are the most common inherited paediatric neurodegenerative disorder. Although genetically distinct, NCLs can be broadly divided into two categories: one in which the mutation results in a defect in a transmembrane protein, and the other where the defect lies in a soluble lysosomal enzyme. A number of therapeutic approaches are applicable to the soluble lysosomal forms of NCL based on the phenomenon of cross-correction, whereby the ubiquitously expressed mannose 6-phosphate/IGF (insulin-like growth factor) II receptor provides an avenue for endocytosis, trafficking and lysosomal processing of extracellularly delivered enzyme. The present review discusses therapeutic utilization of cross-correction by enzyme-replacement therapy, gene therapy and stem cell therapy for the NCLs, along with an overview of the recent progress in translating these treatments into the clinic.
Skip Nav Destination
Article navigation
December 2010
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
Conference Article|
November 24 2010
Current therapies for the soluble lysosomal forms of neuronal ceroid lipofuscinosis
Andrew M.S. Wong;
Andrew M.S. Wong
1
*Pediatric Storage Disorders Laboratory, Department of Neuroscience and Centre for the Cellular Basis of Behaviour, MRC Centre for Neurodegeneration Research, James Black Centre, Institute of Psychiatry, King's College London, 125 Coldharbour Lane, London SE5 9NU, U.K.
1Correspondence may be addressed to either of these authors (email andrew.2.wong@kcl.ac.uk or jon.cooper@kcl.ac.uk).
Search for other works by this author on:
Ahad A. Rahim;
Ahad A. Rahim
†Gene Transfer Technology Group, Institute for Women's Health, 86–96 Chenies Mews, University College London, London WC1E 6HX, U.K.
Search for other works by this author on:
Simon N. Waddington;
Simon N. Waddington
†Gene Transfer Technology Group, Institute for Women's Health, 86–96 Chenies Mews, University College London, London WC1E 6HX, U.K.
Search for other works by this author on:
Jonathan D. Cooper
Jonathan D. Cooper
1
*Pediatric Storage Disorders Laboratory, Department of Neuroscience and Centre for the Cellular Basis of Behaviour, MRC Centre for Neurodegeneration Research, James Black Centre, Institute of Psychiatry, King's College London, 125 Coldharbour Lane, London SE5 9NU, U.K.
1Correspondence may be addressed to either of these authors (email andrew.2.wong@kcl.ac.uk or jon.cooper@kcl.ac.uk).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
August 31 2010
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© The Authors Journal compilation © 2010 Biochemical Society
2010
Biochem Soc Trans (2010) 38 (6): 1484–1488.
Article history
Received:
August 31 2010
Citation
Andrew M.S. Wong, Ahad A. Rahim, Simon N. Waddington, Jonathan D. Cooper; Current therapies for the soluble lysosomal forms of neuronal ceroid lipofuscinosis. Biochem Soc Trans 1 December 2010; 38 (6): 1484–1488. doi: https://doi.org/10.1042/BST0381484
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.